Squire Patton Boggs Advises Baird Capital on Investment in Life Sciences Consultancy Newmarket Strategy

View Contact / News /London

Squire Patton Boggs has advised Baird Capital on a growth capital investment in Newmarket Strategy, an independent life sciences consultancy and market access specialist. The investment will support the company’s continued growth as an independent leader in pharmaceutical services and healthcare advisory.

The Squire Patton Boggs team advising Baird Capital was led by Corporate partner Mark Yeo and senior associate Matt Lappin.

Founded in London in 2021, Newmarket Strategy applies deep expertise on the policies, processes and technical requirements which govern the reimbursement of health and life sciences products. Its mission is to drive access to health innovations which have the power to improve, transform and save lives. The team works with clients to assess market opportunities, secure reimbursement from national and local payors, and drive the uptake of health innovations. Clients include global pharmaceuticals and biotech, med-tech, diagnostics, digital health, private equity and healthcare services providers.

Press Contacts

Angelo Kakolyris +1 973 848 5621